1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Icure Pharmaceutical Incorporation
  6. Summary
    A175250   KR7175250000

ICURE PHARMACEUTICAL INCORPORATION

(A175250)
  Report
End-of-day quote Korea Stock Exchange  -  2022-08-11
12800.00 KRW   -1.54%
05/16Icure Pharmaceutical Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
03/23Icure Pharmaceutical Incorporation Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/11Tranche Update on Icure Pharmaceutical Incorporation's Equity Buyback Plan announced on February 25, 2022.
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
08/08/2022 08/09/2022 08/10/2022 08/11/2022 08/12/2022 Date
13400 13200 12750 13000 12800 Last
68884 70807 110048 110618 45896 Volume
-1.83% -1.49% -3.41% +1.96% -1.54% Change
Estimated financial data (e)
Sales 2020 90 144 M - -
Net income 2020 -12 614 M - -
Net Debt 2020 45 079 M - -
P/E ratio 2020 -34,9x
Yield 2020 -
Sales 2021 64 283 M - -
Net income 2021 -38 167 M - -
Net Debt 2021 49 769 M - -
P/E ratio 2021 -8,60x
Yield 2021 -
Capitalization 241 B 185 M -
EV / Sales 2020 5,68x
EV / Sales 2021 6,05x
Nbr of Employees 143
Free-Float 81,5%
More Financials
Company
Icure Pharmaceutical Incorporation is a Korea-based company mainly engaged in the production and sale of cosmetics. Along with subsidiaries, the Company operates its business through two segments. The Cosmetic segment is involved in the manufacturing and sale of cosmetics including basic cosmetics, mask packs, and patches. In addition, it is also engaged in the production and sale of body, hair care products and... 
Sector
Personal Products
Calendar
08/17Earnings Release
More about the company
All news about ICURE PHARMACEUTICAL INCORPORATION
05/16Icure Pharmaceutical Incorporation Reports Earnings Results for the First Quarter Ended..
CI
03/23Icure Pharmaceutical Incorporation Reports Earnings Results for the Full Year Ended Dec..
CI
03/11Tranche Update on Icure Pharmaceutical Incorporation's Equity Buyback Plan announced on..
CI
03/07Icure Pharmaceutical Incorporation's Equity Buyback announced on February 25, 2022, has..
CI
02/25Icure Pharmaceutical Incorporation announces an Equity Buyback for 40,323 shares.
CI
02/25Icure Pharmaceutical Incorporation authorizes a Buyback Plan.
CI
2021Icure Acquires Drug Product Approval for Donepezil Patch for Treating Dementia of the A..
CI
2021Icure Pharmaceutical Incorporation Reports Earnings Results for the Third Quarter and N..
CI
2021Icure Pharmaceutical Incorporation announced that it has received KRW 50 billion in fun..
CI
2021Icure Pharmaceutical Incorporation announced that it expects to receive KRW 50 billion ..
CI
2020Prostemics Co., Ltd. agreed to acquire OTKCNT Co., Ltd. from Icure Pharmaceutical Incor..
CI
2020Icure Pharm. Inc. cancelled the acquisition of 90% stake in OTKCNT Co., Ltd. from an un..
CI
2019Icure Pharm. Inc.'s Equity Buyback announced on August 8, 2019, has expired.
CI
2019Icure Pharm. Inc. announces an Equity Buyback for 153,061 shares.
CI
2019Icure Pharm. Inc. authorizes a Buyback Plan.
CI
More news
News in other languages on ICURE PHARMACEUTICAL INCORPORATION
05/16Icure Pharmaceutical Incorporation annonce ses résultats pour le premier trimestre se t..
03/23Icure Pharmaceutical Incorporation annonce ses résultats pour l'exercice complet termin..
02/25ICURE PHARMACEUTICAL INCORPORATION ( : A175250) annonce un rachat d'actions pour 40 323 ac..
02/25Icure Pharmaceutical Incorporation autorise un plan de rachat.
More news
Chart ICURE PHARMACEUTICAL INCORPORATION
Duration : Period :
Icure Pharmaceutical Incorporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ICURE PHARMACEUTICAL INCORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Managers and Directors
Choi Young Chief Executive Officer & Director
Hyeon-Sik Jeong Director & Head-Research
Yoon-Taek Jeong Independent Director
Sang-Yoon Jeong Director & Head-Pharmaceutical Business
Young-Hoon Kook Executive Board Member & Head-Sales
Sector and Competitors